Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogenic bone marrow mesenchymal stem cells (NIBMT)
- Development stage
- Unknown
- Lead developer
- Guangzhou Saliai Stem Cell Science and Technology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogenic bone marrow mesenchymal stem cells (MSCs) developed by the National Institute of Blood and Marrow Transplant (NIBMT) in Pakistan are an investigational cell therapy for the treatment of steroid-refractory graft-versus-host disease (GVHD). These MSCs are derived from allogenic human bone marrow and ex-vivo expanded using pooled human platelet lysate. MSCs exert their therapeutic effect through potent immunomodulatory and anti-inflammatory properties, including the secretion of paracrine factors and direct cell-to-cell interactions that suppress the activation and proliferation of T cells and other immune effectors involved in the pathogenesis of GVHD. This therapy is currently being evaluated in Phase I/II clinical trials to establish safety and efficacy in patients who have failed first-line corticosteroid treatment following haematopoietic stem cell transplantation.
- Other names
- Allogenic Human Bone Marrow Mesenchymal Stem CellsMesenchymal Stem Cells
Beyond the preview
Go deeper on allogenic bone marrow mesenchymal stem cells (NIBMT).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogenic bone marrow mesenchymal stem cells (NIBMT).